Medizone Intl. (fka MZEIQ)

[17yr_man]

There is a chicken and egg argument around the strategy Dodds has articulated. With the appointment of him and his off-sider they have established enough of a business organization to get on with the job of selling Asure. The company has to trade its way out of the current predicament and not rely on an injection of $5m to instantly solve the cash flow issues they face, historical as they may be. It reeks of the Groundell fiasco we suffered years ago. Who on earth is going to inject this sort of money without obvious sales prospects existing and the SP sitting where it is - the cost in dilution will be horrendous.

We are not hearing about specific selling efforts and that is what concerns me most. FDA approval is required for North American markets but what about Europe ? We need to look at alliances with the likes of the Swedish company mentioned a few weeks ago who are already sold on the benefits of O3 and who are logical, well resourced partners. Reinventing the wheel with the likes of Aglon makes no sense. I hope this type of thinking may be occurring in the background but it is not obvious !